Timothy P. Kelly is COO at Homology Medicines, Inc. (FIXX). They have made 3 open-market trades across 2 companies since 2019, most recently 2026-02-25.
CIK 0001754067
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| FIXX | 2,224 | $37K |
| CRBU | 73,125 | $32K |
| Total | $70K |
Shares reported on the most recent Form 4, priced at the 2026-02-27 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CRBU | SELL | 2026-02-25 | 2026-02-27 | $1.93 | $12K | +10.7% | -3.4% | +29.8% |
| CRBU | SELL | 2026-02-24 | 2026-02-24 | $1.96 | $6K | -15.3% | -10.7% | +0.2% |
| FIXX | SELL · 10b5-1 | 2022-01-05 | 2022-01-12 | $3.78 | $5K | -6.5% | +1.3% | -40.4% |
| FIXX | SELL · 10b5-1 | 2021-09-03 | 2021-09-08 | $7.70 | $416 | +11.8% | -12.3% | -33.4% |
| FIXX | SELL | 2021-03-01 | 2021-03-03 | $11.16 | $139K | +11.8% | -12.3% | -33.4% |
| FIXX | SELL · 10b5-1 | 2021-02-02 | 2021-02-05 | $13.00 | $7K | -14.5% | -32.8% | -55.4% |
| FIXX | SELL · 10b5-1 | 2021-02-01 | 2021-02-03 | $12.37 | $49K | +7.0% | -27.2% | -50.5% |
| FIXX | SELL · 10b5-1 | 2021-01-12 | 2021-01-14 | $13.00 | $7K | -4.4% | +6.6% | -44.7% |
| FIXX | SELL · 10b5-1 | 2021-01-04 | 2021-01-06 | $11.50 | $46K | +9.8% | +14.4% | -22.8% |
| FIXX | SELL · 10b5-1 | 2020-03-17 | 2020-03-18 | $13.01 | $17K | +29.5% | +7.7% | +24.4% |
| FIXX | SELL · 10b5-1 | 2019-09-05 | 2019-09-09 | $19.94 | $23K | -4.9% | -33.8% | -18.1% |
| FIXX | SELL · 10b5-1 | 2019-06-03 | 2019-06-05 | $20.00 | $26K | -3.3% | -7.9% | -4.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.